Analysis of The Use of PCSK9 Inhibitors in Clinical Practice by S. Yu. Volkova, L. A. Boyarskaya, P. Yu. Toropygin, I. A. Morozov, E. A. Boyarskaya

Subjects: “…pcsk9 inhibitor…”
Get full text

Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan by Kuan-Chieh Tu, Wei-Ting Chang, Hui-Wen Lin, Po-Lin Lin, Yen-Wen Wu, Chao-Feng Lin, Hung-I. Yeh, Min-Ji Charng, Po-Hsun Huang, Tsung-Hsien Lin, Wei-Wen Lin, I.-Chang Hsieh, Feng-Yu Kuo, Ching-Pei Chen, Sheng-Hsiang Lin, Yi-Heng Li

Subjects: Get full text

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis by Shengxuan Zhang, Lei Sun, Xinyu Xu, Yanling Zhang, Qilan Chen

Subjects: Get full text

Design of the “EAST” strategy in patients with symptomatic intracranial atherosclerotic stenosis by Jiaqi Dai, Haobo Zhao, Xinyu Chen, Ping Nie, Jie Gong, Min Wang, Kezhong Zhang, Zhaolu Wang, Hua Lu

Subjects: Get full text

Evaluation of Intensive Statins and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Intracranial Artery Plaque Stability: A Prospective Single‐Arm Study by Weiqi Zeng, Feng Zhou, Hai Zhao, Yukai Wang, Jingjuan Chen, Jiancong Lu, Dezhi Zheng, Jingyun Kuang, Dahua Yuan, Jing Zhou, Changzheng Shi, Xihai Zhao, Xinyi Leng, Bernard Yan, Zefeng Tan

Subjects: Get full text

Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone by Xinzhi Hu, Yiyang Liu, Weizhuang Yuan, Zongmuyu Zhang, Shun Li, Anqi Cheng, Qiuyu Yu, Haoyao Guo, Yinxi Zou, Mingli Li, Caiyan Liu, Yan Xu, Weihai Xu

Subjects: Get full text

Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare by A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, A. S. Bezymyanny, E. L. Kordzaya, E. Yu. Vasilyeva

Subjects: Get full text

Observational study of inclisiran effectiveness in Moscow healthcare by A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, A. S. Bezymyannyy, E. Yu. Vasilyeva

Subjects: Get full text

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression by Maram H. Abduljabbar

Subjects: “…PCSK9 inhibitors…”
Get full text

PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk by Radosław Szydłowski, Magdalena Bodera, Hanna Porwolik, Agata Porwolik, Patrycja Pabis, Agnieszka Porwolik, Dominik Rabstein, Piotr Gościniewicz

Subjects: “…PCSK9 inhibitors…”
Get full text

Atherosclerosis and inflammation – the path from pathogenesis to treatment: review of the current state of the issue (part 2) by A. A. Avagimyan, L. V. Kaktursky, O. I. Urazova, A. I. Trofimenko, L. M. Sukiasyan, E. A. Kogan, T. A. Demura, N. V. Pogosova

Subjects: Get full text

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome by A. M. Namitokov, V. K. Zafiraki, K. V. Karabakhtsieva

Subjects: Get full text

Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues by M. V. Zhuravleva, A. B. Prokofiev, E. V. Shikh, S. Yu. Serebrova, G. I. Gorodetskaya, E. Yu. Demchenkova

Subjects: “…pcsk9 inhibitors…”
Get full text

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders by O. L. Barbarash, N. V. Fedorova, D. Yu. Sedykh, O. V. Gruzdeva, O. N. Khryachkova, V. V. Kashtalap, A. A. Filimonova

Subjects: Get full text

Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis by Leyu Xu, Leyu Xu, Ming Lei, Ming Lei, Liren Li, Liren Li, Yilei Li, Yilei Li, Chunping Gu, Chunping Gu, Ping Zheng, Ping Zheng

Subjects: Get full text

HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW by M. G. Bubnova

Subjects: Get full text

PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome by Wang Liang, Wang Ruijie, Jiao Tiantian, Xu Linghao, Ji Endong, Jiang Yuanzhen, Wang Yuanqi, Liu Yehong, Li Jiming

Subjects: “…pcsk9 inhibitors…”
Get full text

PCSK9 in T-cell function and the immune response by Yuying Wang, Xiaosheng Fang, Jiarui Liu, Xiao Lv, Kang Lu, Yingxue Lu, Yujie Jiang

Subjects: Get full text

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis by Bohan Luo, Zhuang Sun, Han Luo

Subjects: “…PCSK9 inhibitors…”
Get full text

Cardiovascular risk management beyond statins: review of new therapies available in Italy by Maurizio Capuozzo, Alessandro Ottaiano, Claudia Cinque, Stefania Farace, Francesco Ferrara

Subjects: Get full text